300119 瑞普生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,720,4600.75%3,398,4583,069,9332,709,1052,084,250
减:营业总成本1,487,8791.61%3,020,0872,690,1402,327,4071,731,931
    其中:营业成本1,036,9314.80%1,995,6631,799,7231,526,7841,074,613
               财务费用17,451-2.87%34,65827,20620,55017,347
               资产减值损失22-94.14%(6,845)(19,850)580473
公允价值变动收益10,087-76.70%75,831(10,708)61,26051,383
投资收益6,666-79.23%34,2229,14315,1514,051
    其中:对联营企业和合营企业的投资收益(994)-143.78%12,4253,79421,355828
营业利润240,059-23.09%479,585373,168569,746416,638
利润总额240,985-22.64%470,691368,289571,189413,811
减:所得税费用19,070-51.65%36,22138,45556,18440,042
净利润221,915-18.43%434,469329,834515,004373,770
减:非控股权益17,81014.60%33,95629,11261,41127,071
股东净利润204,105-20.43%400,513300,722453,594346,699

市场价值指针
每股收益 (元) *0.450-20.33%0.8820.6530.9790.749
每股派息 (元) *----0.4000.3000.4000.300
每股净资产 (元) *10.1263.16%10.1209.5959.6439.020
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容